Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Lymphoma, Large B-Cell, Diffuse 33Lymphoma, Mantle-Cell 24Burkitt Lymphoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Follicular 17Leukemia, Lymphocytic, Chronic, B-Cell 15Lymphoma, B-Cell, Marginal Zone 12Lymphoma, B-Cell 12Lymphoma, Non-Hodgkin 11Hodgkin Disease 8Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 6Leukemia, Biphenotypic, Acute 6Leukemia, Myelomonocytic, Chronic 5Leukemia, Myeloid, Accelerated Phase 5Waldenstrom Macroglobulinemia 4Lymphoma, T-Cell 4Lymphoma 4Blast Crisis 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Chronic-Phase 3Hematologic Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Hairy Cell 2Composite Lymphoma 2Anemia, Refractory, with Excess of Blasts 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Neoplasm, Residual 1Myeloproliferative Disorders 1

Interventions

Cyclophosphamide 63fludarabine phosphate 40Peripheral Blood Stem Cell Transplantation 34Vincristine 30Methotrexate 30Etoposide 29Cytarabine 28Dexamethasone 27Whole-Body Irradiation 25Doxorubicin 25Mycophenolic Acid 23Prednisone 22Tacrolimus 21Filgrastim 21Busulfan 19Antilymphocyte Serum 18venetoclax 17nelarabine 17Cyclosporine 17Calcium Dobesilate 17merphos 15Rituximab 14Radiotherapy 14Methylprednisolone 13Bortezomib 13pegaspargase 12dexamethasone acetate 11dexamethasone 21-phosphate 11Melphalan 11prednylidene 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × CT-P10 × Clear all
NCT03808610 2026-05-13

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
53 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06738368 2026-05-12

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

University of Washington

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡